Certara Acquires Specialty CRO Synchrogenix

Certara, a technology-enabled drug development and drug safety consultancy, announced its acquisition of specialty contract research organization (CRO) Synchrogenix Information Strategies Inc. Synchrogenix offers regulatory writing and related services to pharmaceutical, biotechnology and medical device companies worldwide. The acquisition allows Certara to provide preclinical and clinical pharmacology customers with end-to-end drug development consulting and writing services, including preparation of regulatory submissions such BLAs, IND, and NDAs. Synchrogenix has 50 permanent regulatory writers and editors on staff, and has seven offices in North America, Europe, and Asia.

Read the full release here.